FATE THERAPEUTICS INC Payments to Acquire Short-term Investments
FATE THERAPEUTICS INC (FATE) reported Payments to Acquire Short-term Investments of $106.18 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2019-11-05
- FATE THERAPEUTICS INC payments to acquire short-term investments for the quarter ending 2019-09-30 was $0.00.
- FATE THERAPEUTICS INC payments to acquire short-term investments for the quarter ending 2018-12-31 was $0.00.
- FATE THERAPEUTICS INC payments to acquire short-term investments for the quarter ending 2018-09-30 was $0.00.
- FATE THERAPEUTICS INC payments to acquire short-term investments for the quarter ending 2018-06-30 was $0.00.
- FATE THERAPEUTICS INC payments to acquire short-term investments for fiscal 2018 was $55.66M, a 39.25% increase from fiscal 2017.
- FATE THERAPEUTICS INC payments to acquire short-term investments for fiscal 2017 was $39.97M, a 103.16% increase from fiscal 2016.
- FATE THERAPEUTICS INC payments to acquire short-term investments for fiscal 2016 was $19.68M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $106.18M 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | $106.18M 10-Q · filed 2019-08-06 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 derived: sum of 3 quarters · filed 2019-11-05 | $55.66M 10-K · filed 2019-03-05 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $55.66M 10-Q · filed 2019-11-05 | $55.66M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $55.66M 10-Q · filed 2019-08-06 | $55.66M derived: sum of 3 quarters · filed 2019-08-06 | $55.66M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $55.66M 10-Q · filed 2019-05-07 | $55.66M derived: sum of 2 quarters · filed 2019-05-07 | $55.66M derived: sum of 3 quarters · filed 2019-05-07 | $55.66M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $0.00 derived: sum of 2 quarters · filed 2019-03-05 | $0.00 derived: sum of 3 quarters · filed 2019-03-05 | $39.97M 10-K · filed 2019-03-05 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $39.97M 10-Q · filed 2018-11-01 | $39.97M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $39.97M 10-Q · filed 2018-08-06 | $39.97M derived: sum of 3 quarters · filed 2019-03-05 | $43.48M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-03-31 | $39.97M 10-Q · filed 2018-05-10 | $39.97M derived: sum of 2 quarters · filed 2019-03-05 | $43.48M derived: sum of 3 quarters · filed 2019-03-05 | $43.48M derived: sum of 4 quarters · filed 2019-03-05 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $3.51M derived: sum of 2 quarters · filed 2019-03-05 | $3.51M derived: sum of 3 quarters · filed 2019-03-05 | $19.68M 10-K · filed 2019-03-05 |
| 2016-09-30 | $3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $3.51M derived: sum of 2 quarters · filed 2017-11-01 | $19.68M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $16.17M 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $16.17M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |